Population-Based Trends in High-Grade Cervical Lesions in the Early Human Papillomavirus Vaccine Era in the United States

Authors

Susan Hariri, Centers for Disease Control and Prevention
Michelle L. Johnson, Centers for Disease Control and Prevention
Nancy M. Bennett, University of Rochester
Heidi M. Bauer, California Department of Public Health
Ina U. Park, California Department of Public Health
Sean Schafer, Oregon Public Health Division
Linda M. Niccolai, Yale School of Public Health
Elizabeth R. Unger, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention
Lauri E. Markowitz, Centers for Disease Control and Prevention

Date of this Version

2015

Citation

Cancer Volume 121, Issue 16, August 15, 2015, Pages: 2775–2781

Comments

U.S. Government Work

Abstract

BACKGROUND: Cervical intraepithelial neoplasia grade 2, 3, and adenocarcinoma in situ (CIN2+) lesions can be monitored as early indicators of human papillomavirus (HPV) vaccine impact. Changes to screening utilization will affect observed reductions in CIN2+ rates and complicate the interpretation of vaccine impact. METHODS: From 2008 to 2012, 9119 cases of CIN2+ among 18- to 39-year-old residents of catchment areas in California, Connecticut, New York, and Oregon were reported to the HPV-IMPACT Project, a sentinel system for monitoring the population impact of HPV vaccine. Age-stratified CIN2+ incidence rates were calculated for each catchment.

Annual cervical screening was estimated for California, New York, and Oregon catchments with administrative and survey data. The Cochran-Armitage test was used to examine trends. RESULTS: From 2008 to 2012, the incidence of CIN2+ significantly

decreased among 18- to 20-year-olds (California, from 94 to 5 per 100,000 women; Connecticut, from 450 to 57 per 100,000 women; New York, from 299 to 43 per 100,000 women; and Oregon, from 202 to 37 per 100,000 women; P_trend<.0001) and among 21- to 29-year-olds in Connecticut (from 762 to 589 per 100,000 women) and New York (from 770 to 465 per 100,000 women; P_trend<.001); rates did not differ among 30- to 39-year-olds. During the same period, screening rates also declined, with the largest

decreases among 18- to 20-year-olds (from 67% in Oregon to 88% in California) and with smaller declines among 21- to 29-year-olds (13%-27%) and 30- to 39-year-olds (3%-21%). CONCLUSIONS: The declines in CIN2+ detection in young women were likely due to reduced screening but could also reflect the impact of vaccination. These data illustrate challenges in interpreting CIN2+ ecologic trends in the new era of cervical cancer prevention and emphasize the importance of information such as HPV types detected in lesions to assess the impact of HPV vaccine on cervical precancers.